Publication at First Faculty of Medicine |
2017
Abstract
Mepolizumab, humanized monoclonal antibody against interleukin-5, is a promising drug for the treatment of eosinophilic syndromes. Eosinophilic syndromes are either primary, clonal or idiopathic, or secondary within another diseases including those induced by clonal expansions.
Mepolizumab represents a targeted treatment, which is an effective alternative of currently used drugs, especially in eosinophilic asthma and idiopathic hypereosinophilic syndrome, where it enables to reach control of the disease without side-effects of corticosteroids and immunosuppressive drugs.